Tag: adamas pharmaceuticals
December 9, 2020
3 Alzheimer’s Disease Treatment Stocks on the NASDAQ
The Alzheimer's disease treatment market is projected to reach US$12.9 billion by 2028. Which stocks should be on investors' radar? January 2, 2020
Adamas Announces Settlement of Patent Litigation with Sandoz
Adamas has entered into a settlement agreement with Sandoz resolving its ongoing litigation concerning Sandoz’s new drug application. September 20, 2019
Adamas Announces Data for GOCOVRI in Parkinson’s Disease
Adamas Pharmaceuticals (NASDAQ:ADMS) has announced presentation of new data on GOCOVRI to treat dyskinesia in patients with Parkinson’s disease. As... December 19, 2018
Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI
Adamas Pharmaceuticals (Nasdaq:ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that a new... October 4, 2018